• Renalytix achieves inclusion on the Final 2020 Clinical Laboratory Fee Schedule (“CLFS”) with a set national price of $950 per reportable test for its KidneyIntelX test platform (effective January 2020 through December 2022).


  • Renalytix raises gross proceeds in follow-on financing on the AIM market, $17.3M.
  • Renalytix announces positive interim study results conducted with leading academic medical centers in the U.S.